Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 20/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4066215 | 0.89 | PARP1 (0.61) | PARP1 | |
| SCHEMBL8272692 | 0.84 | PARP1 (0.78) | PARP1 | |
| SCHEMBL4630002 | 0.83 | PARP1 (0.59) | PARP1 | |
| SCHEMBL4071313 | 0.82 | PARP1 (0.75) | PARP1 | |
| SCHEMBL4725390 | 0.78 | PARP1 (0.66) | PARP1 | |
| SCHEMBL4066767 | 0.77 | PARP1 (0.82) | PARP1 | |
| SCHEMBL6079842 | 0.76 | PARP1 (0.67) | PARP1 | |
| SCHEMBL6080430 | 0.76 | PARP1 (1.00) | PARP1 | |
| SCHEMBL27715458 | 0.75 | PARP1 (0.76) | PARP1 | |
| SCHEMBL14170205 | 0.75 | PARP1 (0.69) | PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2033645-A1 | Isoquinoline derivatives and methods of use thereof | Inotek Pharmaceuticals Corporation (US) | 2009-03-11 | — | — | EP | disclosed |
| EP-1868607-A4 | ISOQUNOLINE COMPOUNDS AND METHODS OF USE THEREOF | INOTEK PHARMACEUTICALS CORP (US) | 2008-05-14 | — | — | EP | disclosed |
| EP-1784186-A4 | METHODS FOR TREATING OR PREVENTING ERECTILE DYSFUNCTION OR URINARY INCONTINENCE | INOTEK PHARMACEUTICALS CORP (US) | 2008-05-14 | — | — | EP | disclosed |
| EP-1868607-A2 | ISOQUNOLINE COMPOUNDS AND METHODS OF USE THEREOF | Inotek Pharmaceuticals Corporation (US) | 2007-12-26 | — | — | EP | disclosed |
| EP-1784186-A2 | METHODS FOR TREATING OR PREVENTING ERECTILE DYSFUNCTION OR URINARY INCONTINENCE | Inotek Pharmaceuticals Corporation (US) | 2007-05-16 | — | — | EP | disclosed |
| US-20060287313-A1 | Isoquinoline compounds and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2006-12-21 | — | — | US | disclosed |
| WO-2006093666-A2 | ISOQUNOLINE COMPOUNDS AND METHODS OF USE THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2006-09-08 | — | — | WO | disclosed |
| WO-2006009718-A2 | METHODS FOR TREATING OR PREVENTING ERECTILE DYSFUNCTION OR URINARY INCONTINENCE | INOTEK PHARMACEUTICALS CORPORATION (US) | 2006-01-26 | — | — | WO | disclosed |
| US-20060019980-A1 | Methods for treating or preventing erectile dysfunction or urinary incontinence | INOTEK PHARMACEUTICAL, CORP. (US) | 2006-01-26 | — | — | US | disclosed |
| US-20050228007-A1 | Isoquinoline derivatives and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION | 2005-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050228007-A1 | Isoquinoline derivatives and methods of use thereof | GLS, PINK1, PARK7 | PARP1 327/4885 |
| US-20060019980-A1 | Methods for treating or preventing erectile dysfunction or urinary incontinence | PDE3A, PDE3B, PDE5A | PARP1 1715/4885 |
| US-20060287313-A1 | Isoquinoline compounds and methods of use thereof | GLS, PINK1, PARK7 | PARP1 256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.